Jian Hua Gu
Amgen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jian Hua Gu.
Pharmaceutical Research | 2018
Jian Hua Gu; Rulin Qian; Robert Y.-T. Chou; Pavel V. Bondarenko; Merrill Seymour Goldenberg
PurposeTo show and rationalize the confounding effects on the rotational/oscillatory rheology of surface active impurities in commercial protein formulations such as bovine serum albumin, BSA.MethodsBulk and interfacial rotational/oscillatory rheology were used to study the viscosity, complex viscosity, storage/elastic modulus, G’ and loss/viscous modulus, G”, as a function of time of aqueous formulations of BSA and their purified components.ResultsViscosity/time profiles at steady shear for different commercial BSA products and lots showed viscosity increase, decrease and time-independent profiles at low shear rates. All lots showed shear thinning. BSA monomer and dimers/aggregates, in general, showed similar profiles. Addition of low levels of surfactant or high shear rates rendered all solutions to be Newtonian-like. Interfacial viscosity studies paralleled those on the rotational rheometer. G’ > G” with viscosity increase and G’ < G” with viscosity decrease over time.ConclusionsWe provide a rational explanation for the time-dependent and source-dependent rheological behavior of aqueous formulations of commercially available BSA proteins based on the migration of protein and surface active impurities to the air/water interface within the rheometer plates leading to the formation and breakdown of protein networks. Highly purified proteins is warranted in rheological studies of protein drug product candidates.
Archive | 2018
Deirdre Murphy Piedmonte; Jian Hua Gu; Stephen R. Brych; Monica M. Goss
Practical issues that arise for high concentration protein formulations can complicate manufacturing and affect injectability/device compatibility. High concentration protein formulations have an increased tendency for high solution viscosity, physical stability sensitivities (aggregation/particulation), and non-Newtonian solution behavior (shear thinning) due to high shear rates. Process unit operations can be negatively impacted by these factors, and it is critical to understand how they influence process performance. Device compatibility can be affected by changes in protein concentration and temperature that will impact product viscosity and injectability. Complete characterization of the solution physical properties (viscosity and shear thinning profile) as well as the stability profile must be understood to ensure efficient processing, delivery, and efficacy of the therapeutic product. If potential candidates with impeding viscosity values are not identified early in development, subsequent mitigation efforts to reduce viscosity likely pivot from a protein engineering approach to changes in formulation.
Archive | 1999
Merrill Seymour Goldenberg; Jian Hua Gu
Archive | 1998
Merrill Seymour Goldenberg; Alice C. Beekman; Jian Hua Gu
Polymer International | 2010
Jian Hua Gu; Yu Jin Huang; Alice C. Beekman; Merrill Seymour Goldenberg
Pharmaceutical Research | 2013
Jian Hua Gu; Alice C. Beekman; Tian Wu; Deirdre Murphy Piedmonte; Priti Baker; Michael Eschenberg; Michael Hale; Merrill Seymour Goldenberg
Archive | 2005
Merrill S. Goldenberg; Jian Hua Gu
Archive | 2005
Merrill S. Goldenberg; Jian Hua Gu
Archive | 1999
Merrill Seymour Goldenberg; Jian Hua Gu
Archive | 1999
Merrill Seymour Goldenberg; Jian Hua Gu